Bipolar disorder and dopamine dysfunction: an indirect approach focusing on tardive movement syndromes in a naturalistic setting

BMC Psychiatry. 2009 Apr 28:9:16. doi: 10.1186/1471-244X-9-16.

Abstract

Background: It has been suggested that dopamine dysfunction may play a role in bipolar disorder (BD). An indirect approach to examine this issue was developed, focusing on associations between dopamine proxy measures observed in BD (dopamine-related clinical traits using tardive movement syndromes as dopamine proxy measure of reference).

Methods: 3459 eligible bipolar patients were enrolled in an observational study. Incidence rates of tardive movement syndromes (tardive dyskinesia and tardive dystonia; TDD) were examined. A priori hypothesized associations between incident TDD and other dopamine proxies (e.g. prolactin-related adverse effects, bipolar symptoms) were tested over a 2 year follow-up period.

Results: The incidence rate of tardive syndromes was 4.1 %. Incident TDD was independently associated not only with use of antipsychotics, but also with more severe bipolar symptoms, other extrapyramidal symptoms and prolactin-related adverse effects of medication.

Conclusion: Apart from the well-known association with antipsychotics, development of TDD was associated with various other dopamine proxy measures, indirectly supporting the notion of generalised dopamine dysregulation in BD.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use
  • Basal Ganglia Diseases / etiology
  • Bipolar Disorder / drug therapy
  • Bipolar Disorder / physiopathology*
  • Dopamine / physiology*
  • Dyskinesia, Drug-Induced / epidemiology
  • Dyskinesia, Drug-Induced / etiology
  • Dyskinesias / epidemiology*
  • Dyskinesias / physiopathology
  • Dystonia / chemically induced
  • Dystonia / epidemiology
  • Female
  • Humans
  • Incidence
  • Male
  • Prolactin / physiology
  • Psychotropic Drugs / adverse effects
  • Psychotropic Drugs / therapeutic use

Substances

  • Antipsychotic Agents
  • Psychotropic Drugs
  • Prolactin
  • Dopamine